Evidence map›Paper›PMID 39339912›Full record

ArticleViruses2024

SARS-CoV-2 Variants from Long-Term, Persistently Infected Immunocompromised Patients Have Altered Syncytia Formation, Temperature-Dependent Replication, and Serum Neutralizing Antibody Escape.

Camille Wouters, Jaiprasath Sachithanandham, Elgin Akin, Lisa Pieterse, Amary Fall, Thao T Truong, Jennifer Dien Bard, Rebecca Yee, David J Sullivan, Heba H Mostafa and 1 more

Abstract read
In one paragraph

Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Mechanisms of sex differences in acute and long COVID sequelae in mice.bioRxiv : the preprint server for biology · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Camille WoutersW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Jaiprasath SachithanandhamW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Elgin AkinW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0001-8824-8809
Lisa PieterseW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Amary FallDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.ORCID 0000-0002-6890-7915
Thao T TruongDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Jennifer Dien BardDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Rebecca YeeDepartment of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.ORCID 0000-0001-5439-4218
David J SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.
Heba H MostafaDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA.ORCID 0000-0003-3248-1761

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00045 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PEKOSZ, ANDREW · 2021 to 2025
$23.3M
Training: Molecular & Cellular Bases of Infectious DiseasesT32AI007417 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Arturo Casadevall · 1994 to 2026
$11.9M
Virology Resource CoreU54CA260492 · NCI · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L, KLEIN, SABRA L. · 2020 to 2024
$10.4M
Bloomberg Philanthropies N/ACenters for Disease Control 75D30121C11061Department of Defense W911QY2090012National Insitutes of Health N272201400007CNCI NIH HHS U54 CA260492NIAID NIH HHS 75N93021C00045NIAID NIH HHS T32 AI007417NIH HHS N75N03021C00045Richard Eliasberg Family Foundation N/A
6 · The paper itself

Abstract

SARS-CoV-2 infection of immunocompromised individuals often leads to prolonged detection of viral RNA and infectious virus in nasal specimens, presumably due to the lack of induction of an appropriate adaptive immune response. Mutations identified in virus sequences obtained from persistently infected patients bear signatures of immune evasion and have some overlap with sequences present in variants of concern. We characterized virus isolates obtained greater than 100 days after the initial COVID-19 diagnosis from two COVID-19 patients undergoing immunosuppressive cancer therapy, wand compared them to an isolate from the start of the infection. Isolates from an individual who never mounted an antibody response specific to SARS-CoV-2 despite the administration of convalescent plasma showed slight reductions in plaque size and some showed temperature-dependent replication attenuation on human nasal epithelial cell culture compared to the virus that initiated infection. An isolate from another patient-who did mount a SARS-CoV-2 IgM response-showed temperature-dependent changes in plaque size as well as increased syncytia formation and escape from serum-neutralizing antibodies. Our results indicate that not all virus isolates from immunocompromised COVID-19 patients display clear signs of phenotypic change, but increased attention should be paid to monitoring virus evolution in this patient population.

Indexed as

Antibodies, NeutralizingAntibodies, ViralCOVID-19Giant CellsImmunocompromised HostSARS-CoV-2Virus ReplicationChlorocebus aethiopsFemaleHumansImmune EvasionMaleMiddle AgedRNA, ViralTemperatureVero CellsAntibodies, NeutralizingAntibodies, ViralRNA, Viralimmunocompromised hostneutralizing antibody escapeSARS-CoV-2syncytiavirus evolution

Identifiers

PMID39339912
PMCPMC11437501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.